Intervenciones nutricionales en el paciente con enfermedad inflamatoria intestinal

Abstract Nutritional strategies have been explored as primary or adjunct therapies for inflammatory bowel disease (IBD). Exclusive enteral nutrition is effective for the induction of remission in Crohn disease and is recommended as a first-line therapy for children. Dietary strategies focus on adjusting the ratio of consumed nutrients that are proinflammatory or antiinflammatory. Treatments with dietary supplements focus on the antiinflammatory effects of the individual supplements (eg, curcumin, omega-3 fatty acids, vitamin D) or their positive effects on the intestinal microbiome (eg, prebiotics, probiotics). This article discusses the role of diets and dietary supplements in the treatment of IBD. Copyright © 2017 Elsevier Inc. All rights reserved. https://pubmed.ncbi.nlm.nih.gov/29413010/ Notas NPro

La curcumina mitiga la disfunción de la barrera epitelial inducida por el sistema inmunitario por Campylobacter jejuni

Abstract Campylobacter jejuni (C. jejuni) is the most common cause of foodborne gastroenteritis worldwide. The bacteria induce diarrhea and inflammation by invading the intestinal epithelium. Curcumin is a natural polyphenol from turmeric rhizome of Curcuma longa, a medical plant, and is commonly used in curry powder. The aim of this study was the investigation of the protective effects of curcumin against immune-induced epithelial barrier dysfunction in C. jejuni infection. The indirect C. jejuni-induced barrier defects and its protection by curcumin were analyzed in co-cultures with HT-29/B6-GR/MR epithelial cells together with differentiated THP-1 immune cells. Electrophysiological measurements revealed a reduction in transepithelial electrical resistance (TER) in infected co-cultures. An increase in fluorescein (332 Da) permeability in co-cultures as well as in the germ-free IL-10-/- mouse model after C.

El efecto protector de la curcumina sobre la inflamación intestinal inducida por TNBS se media a través de la vía JAK/STAT

Abstract Background: Curcumin displays a protective role in rat models of intestinal inflammation. However, the mechanism of how curcumin affects on intestinal inflammation is less known. The purpose of the current study is to explore the signal pathway in which the curcumin protecting rat from intestinal inflammation. Methods: The intestinal inflammation rat models were made by TNBS treatment. Curcumin was added to their diet 5 days before the TNBS instillation. After that, body weight change, score of macroscopic assessment of disease activity and microscopic scoring were utilized to analyse the severity of the induced inflammation. In addition, the level of pro-inflammatory cytokines and anti-inflammatory were detected to determine the effect of curcumin on intestinal inflammation. The JAK/STAT pathway of pro-inflammation response was

Acción anti-apoptótica de la curcumina en un modelo de daño inflamatorio epitelial intestinal

Abstract The purpose of this study is to determine if a preventive treatment with curcumin can protect intestinal epithelial cells from inflammatory damage induced by IFNγ. To achieve this goal we have used a human intestinal epithelial cell line (HT29) treated with IFNγ to undergo apoptotic changes that can reproduce the damage of intestinal epithelia exposed to inflammatory cytokines. In this model, we measured the effect of curcumin (curcuminoid from Curcuma Longa) added as a pre-treatment at different time intervals before stimulation with IFNγ. Curcumin administration to HT29 culture before the inflammatory stimulus IFNγ reduced the cell apoptosis rate. This effect gradually declined with the reduction of the curcumin pre-incubation time. This anti-apoptotic action by curcumin pre-treatment was paralleled by a

Efecto protector de la curcumina contra la lesión de la mucosa intestinal inducida por irinotecán a través de la atenuación de la activación de NF-B, estrés oxidativo y estrés retículo endoplasmático

Abstract Irinotecan (CPT‑11) is a DNA topoisomerase I inhibitor which is widely used in clinical chemotherapy, particularly for colorectal cancer treatment. However, late‑onset diarrhea is one of the severe side‑effects of this drug and this restricts its clinical application. The present study aimed to investigate the protective effects of curcumin treatment on CPT‑11‑induced intestinal mucosal injury both in vitro and in vivo and to elucidate the related mechanisms involved in these effects. For this purpose, mice were intraperitoneally injected with CPT‑11 (75 mg/kg) for 4 days to establish a model of late‑onset diarrhea. Curcumin (100 mg/kg) was intragastrically administered 8 days before the injection of CPT‑11. Injury to small intestinal tissues was examined by H&E staining. The protein expression of

Avances en la investigación del efecto protector de la curcumina en la función de barrera mucosa intestinal

Abstract As a natural extract from turmeric, curcumin has extensive pharmacological effects, such as anti-tumor, anti-inflammation, anti-oxidative stress, anti-microbial, immunoregulation and so on. In recent years, an increasing number of basic and clinical researches have shown that curcumin takes therapeutic effects on various diseases, such as gastrointestinal diseases, cardiovascular diseases, autoimmune diseases, neuropsychiatric diseases and so on. Many of the pharmacological effects and mechanisms of curcumin are associated with protective effects of intestinal mucosal barrier. It can protect intestinal mucosal barrier through mutiple pathways, including anti-inflammation, anti-oxidative stress, anti-bacterial, anti-apoptosis, regulating intestinal microecology and intestinal immune response and so on. This paper summarizes the protective effects of curcumin on intestinal barrier function and the mechanism, in order to provide new

La curcumina y el resveratrol regulan las bacterias intestinales y alivian la inflamación intestinal en lechones destetados

Abstract Human infants or piglets are vulnerable to intestinal microbe-caused disorders and inflammation due to their rapidly changing gut microbiota and immaturity of their immune systems at weaning. Resveratrol and curcumin have significant anti-inflammatory, bacteria-regulating and immune-promoting effects. The purpose of this study was to investigate whether dietary supplementation with resveratrol and curcumin can change the intestinal microbiota and alleviate intestinal inflammation induced by weaning in piglets. One hundred eighty piglets weaned at 21 ± 2 d were fed a control diet (CON group) or supplemented diet (300 mg/kg of antibiotics, ANT group; 300 mg/kg of resveratrol and curcumin, respectively, HRC group; 100 mg/kg of resveratrol and curcumin, respectively, LRC group; 300 mg/kg of resveratrol, RES group; 300 mg/kg of

La curcumina mejora la función de barrera intestinal: modulación de la señalización intracelular y organización de uniones estrechas

Abstract Association between circulating lipopolysaccharide (LPS) and metabolic diseases (such as type 2 diabetes and atherosclerosis) has shifted the focus from high-fat high-cholesterol containing Western-type diet (WD)-induced changes in gut microbiota per se to release of gut bacteria-derived products (e.g., LPS) into circulation due to intestinal barrier dysfunction as the possible mechanism for the chronic inflammatory state underlying the development of these diseases. We demonstrated earlier that oral supplementation with curcumin attenuates WD-induced development of type 2 diabetes and atherosclerosis. Poor bioavailability of curcumin has precluded the establishment of a causal relationship between oral supplementation and it is in vivo effects. We hypothesized that curcumin attenuates WD-induced chronic inflammation and associated metabolic diseases by modulating the function of intestinal epithelial

Curcumina y Enfermedades Inflamatorias Intestinales: Mecanismos Moleculares de Protección

Abstract Objective: To investigate the anti-ulcerative colitis mechanism of resveratrol through regulation of Wnt/β-catenin signaling pathway. Intestinal inflammatory diseases, such as Crohn’s disease, ulcerative colitis, and necrotizing enterocolitis, are becoming increasingly prevalent. While knowledge of the pathogenesis of these related diseases is currently incomplete, each of these conditions is thought to involve a dysfunctional, or overstated, host immunological response to both bacteria and dietary antigens, resulting in unchecked intestinal inflammation and, often, alterations in the intestinal microbiome. This inflammation can result in an impaired intestinal barrier allowing for bacterial translocation, potentially resulting in systemic inflammation and, in severe cases, sepsis. Chronic inflammation of this nature, in the case of inflammatory bowel disease, can even spur cancer growth in the longer-term. Recent

Últimas Entradas

¡GRACIAS!

Solicitud  RECIBIDA

En el plazo de 24-48 horas nos pondremos en contacto con ud. para informarle y facilitarle sus datos de acceso.

CONCENTIMIENTO

Política de privacidad

En la presente Política de Privacidad, le informamos sobre la recopilación, tratamiento y uso de sus datos personales recabados por Natural Probiotics S.L.. mediante la utilización de la presente página web.

Responsable del tratamiento:

Identidad: Natural Probiotics S.L.

Domicilio social: Passeig Irlanda 16, Local Bajo., 08030, Barcelona

C.I.F. nº: B67286245

Email: privacidad@naturalprobiotics.es

Tras la lectura del presente documento y /o con la aceptación de nuestras condiciones de servicios en el proceso de registro como cliente particular o profesional consiente el tratamiento de sus datos para las finalidades que se detallarán a continuación por parte de Natural Probiotics.

De conformidad con lo establecido en los arts. 6.1.a), 7 Y 8 del REGLAMENTO (UE) 2016/679 DEL PARLAMENTO EUROPEO Y DEL CONSEJO de 27 de abril de 2016, relativo a la protección de las personas físicas en lo que respecta al tratamiento de datos personales le comunicamos que los datos que usted nos facilite quedarán incorporados y serán tratados en los ficheros titularidad del responsable del tratamiento Natural Probiotics S.L..

¿Por qué y para qué tratamos tus datos?

En Natural Probiotics tratamos la información que nos facilitan las personas interesadas con las siguientes finalidades:

Gestionar pedidos o contratar alguno de nuestros servicios, ya sea online o en las tiendas físicas.

Gestionar el envío de la información que nos soliciten.

Desarrollar acciones comerciales y realizar el mantenimiento y gestión de la relación con el usuario.

¿Cuál es la legitimación para el tratamiento de tus datos?

 

El tratamiento de tus datos puede fundamentarse en las siguientes bases legales:

Ejecución de un contrato o en la prestación de un servicio en base a una relación comercial que cuenta con el consentimiento del interesado.

Interés legítimo para el envío de información comercial sobre productos y servicios (marketing directo).

Interés legítimo para el contacto y mantenimiento de la relación con clientes y proveedores.

Cumplimiento de obligaciones legales para prevención del fraude, comunicación con Autoridades públicas y reclamaciones de terceros.

Consentimiento explícito del usuario para la elaboración de perfiles, los formularios de contacto, las solicitudes de información o alta en e-newsletters.

¿A qué destinatarios se comunican sus datos?

En algunos casos, solo cuando sea necesario, Natural Probiotics proporcionará datos de los usuarios a terceros. Sin embargo, nunca se venderán los datos a terceros. Los proveedores de servicios externos (por ejemplo, proveedores de pago o empresas de reparto) con los que Natural Probiotics trabaje pueden usar los datos para proporcionar los servicios correspondientes, sin embargo no usarán dicha información para fines propios o para cesión a terceros. Dichos proveedores tienen la obligación de garantizar que la información se trata conforme con la normativa de privacidad de datos.

En algunos casos, la ley puede exigir que se revelen datos personales a organismos públicos u otras partes, solo se revelará lo estrictamente necesario para el cumplimiento de dichas obligaciones legales.

Los datos personales obtenidos también podrán ser compartidos con otras empresas del grupo.

¿Qué derechos le asisten y cómo puede ejercerlos?

Puede dirigir sus comunicaciones y ejercitar sus derechos mediante una petición en el siguiente correo electrónico: privacidad@naturalprobiotics.es. En virtud de lo que establece el RGPD puedes solicitar derecho de acceso, derecho de rectificación, derecho de supresión y al olvido, derecho de limitación al tratamiento, derecho de oposición, derecho a la portabilidad y derecho a no ser objeto de decisiones individualizadas.